Deutsche Bank AG Lowers Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Key Points

• Deutsche Bank AG reduced its stake in Thermo Fisher Scientific by 4.4% in the first quarter, resulting in ownership of approximately $628.76 million worth of shares.
• Several hedge funds modified their holdings of Thermo Fisher, with notable increases from Brighton Jones LLC (28.9%) and Renaissance Technologies LLC (270.5%) during the fourth quarter.
• Thermo Fisher reported a quarterly EPS of $5.36, exceeding estimates, along with a revenue of $10.86 billion, up 2.9% year-over-year.

Deutsche Bank AG lowered its position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 4.4% in the 1st quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,263,590 shares of the medical research company's stock after selling 58,043 shares during the period. Deutsche Bank AG owned 0.33% of Thermo Fisher Scientific worth $628,762,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in TMO. Bernard Wealth Management Corp. bought a new stake in shares of Thermo Fisher Scientific during the 4th quarter valued at $25,000. Ameriflex Group Inc. purchased a new position in Thermo Fisher Scientific during the 4th quarter valued at about $30,000. IMA Advisory Services Inc. bought a new stake in Thermo Fisher Scientific during the first quarter worth about $35,000. Navigoe LLC bought a new position in shares of Thermo Fisher Scientific during the fourth quarter valued at approximately $37,000. Finally, Smallwood Wealth Investment Management LLC purchased a new position in shares of Thermo Fisher Scientific during the first quarter valued at approximately $37,000. 89.23% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

TMO has been the topic of several recent research reports. Raymond James Financial restated an "outperform" rating and issued a $535.00 price target (up previously from $525.00) on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Hsbc Global Res lowered Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 24th. HSBC reissued a "hold" rating and set a $510.00 price objective on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Argus dropped their target price on shares of Thermo Fisher Scientific from $620.00 to $470.00 and set a "buy" rating on the stock in a research note on Tuesday, April 29th. Finally, Robert W. Baird raised their price target on shares of Thermo Fisher Scientific from $553.00 to $567.00 and gave the company an "outperform" rating in a research report on Thursday, July 24th. Six investment analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $593.00.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 10,000 shares of the business's stock in a transaction that occurred on Wednesday, August 6th. The stock was sold at an average price of $451.82, for a total transaction of $4,518,200.00. Following the completion of the transaction, the chief executive officer directly owned 115,174 shares in the company, valued at approximately $52,037,916.68. The trade was a 7.99% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Gianluca Pettiti sold 400 shares of the firm's stock in a transaction that occurred on Friday, July 25th. The stock was sold at an average price of $479.98, for a total transaction of $191,992.00. Following the sale, the executive vice president owned 22,367 shares in the company, valued at approximately $10,735,712.66. The trade was a 1.76% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 18,400 shares of company stock worth $8,345,792 over the last quarter. 0.33% of the stock is owned by company insiders.

Thermo Fisher Scientific Stock Performance

Thermo Fisher Scientific stock traded up $6.60 during mid-day trading on Friday, reaching $461.34. 1,689,914 shares of the stock traded hands, compared to its average volume of 3,227,669. The stock has a market capitalization of $174.21 billion, a PE ratio of 26.68, a price-to-earnings-growth ratio of 2.43 and a beta of 0.74. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50. The business's 50-day moving average is $426.80 and its 200-day moving average is $464.17. Thermo Fisher Scientific Inc. has a 12-month low of $385.46 and a 12-month high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, topping the consensus estimate of $5.22 by $0.14. The firm had revenue of $10.86 billion for the quarter, compared to analysts' expectations of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The business's quarterly revenue was up 2.9% on a year-over-year basis. During the same quarter in the prior year, the business earned $5.37 EPS. As a group, sell-side analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be given a dividend of $0.43 per share. The ex-dividend date is Monday, September 15th. This represents a $1.72 annualized dividend and a yield of 0.4%. Thermo Fisher Scientific's payout ratio is 9.95%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.